MX2024012370A - Proceso mejorado para la fabricacion de osimertinib - Google Patents

Proceso mejorado para la fabricacion de osimertinib

Info

Publication number
MX2024012370A
MX2024012370A MX2024012370A MX2024012370A MX2024012370A MX 2024012370 A MX2024012370 A MX 2024012370A MX 2024012370 A MX2024012370 A MX 2024012370A MX 2024012370 A MX2024012370 A MX 2024012370A MX 2024012370 A MX2024012370 A MX 2024012370A
Authority
MX
Mexico
Prior art keywords
osimertinib
manufacture
improved process
improved
specification relates
Prior art date
Application number
MX2024012370A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Kieron Mullen
Alessandro Pozzoli
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2024012370A publication Critical patent/MX2024012370A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2024012370A 2022-04-07 2024-10-04 Proceso mejorado para la fabricacion de osimertinib MX2024012370A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362622P 2022-04-07 2022-04-07
PCT/EP2023/059132 WO2023194531A1 (en) 2022-04-07 2023-04-06 Improved process for the manufacture of osimertinib

Publications (1)

Publication Number Publication Date
MX2024012370A true MX2024012370A (es) 2024-11-08

Family

ID=86142780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012370A MX2024012370A (es) 2022-04-07 2024-10-04 Proceso mejorado para la fabricacion de osimertinib

Country Status (14)

Country Link
US (1) US20250250255A1 (https=)
EP (1) EP4504718A1 (https=)
JP (1) JP2025511404A (https=)
KR (1) KR20250002363A (https=)
CN (1) CN119317624A (https=)
AR (1) AR128999A1 (https=)
AU (1) AU2023250220A1 (https=)
CA (1) CA3255378A1 (https=)
CO (1) CO2024015096A2 (https=)
IL (1) IL316018A (https=)
MX (1) MX2024012370A (https=)
TW (1) TW202404955A (https=)
WO (1) WO2023194531A1 (https=)
ZA (1) ZA202408113B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120717920A (zh) * 2025-08-18 2025-09-30 爱斯特（成都）生物制药股份有限公司 一种微通道连续合成3-硝基-4-氟苯腈的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
IN201741031902A (https=) * 2017-09-08 2019-03-15 Msn Laboratories Private Ltd
CN109134435B (zh) 2018-10-29 2023-01-03 湖南大学 一种奥希替尼azd9291的合成方法

Also Published As

Publication number Publication date
JP2025511404A (ja) 2025-04-15
CN119317624A (zh) 2025-01-14
AR128999A1 (es) 2024-07-03
ZA202408113B (en) 2025-07-30
KR20250002363A (ko) 2025-01-07
TW202404955A (zh) 2024-02-01
WO2023194531A1 (en) 2023-10-12
AU2023250220A1 (en) 2024-11-07
IL316018A (en) 2024-11-01
CO2024015096A2 (es) 2024-11-28
EP4504718A1 (en) 2025-02-12
CA3255378A1 (en) 2023-10-12
US20250250255A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
MX2022001829A (es) Proceso de fabricación de moduladores de regulador de conductancia transmembrana de la fibrosis quística (cftr).
PH12021553000A1 (en) Multispecific proteins
MY194660A (en) Alkoxycarbonylation of trivinylcyclohexane
PH12021550403A1 (en) Process of making calcium alpha-ketoglutarate
MX2021003070A (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino.
MY197889A (en) Microorganism producing l-amino acid and method for producing l-amino acid using the same
ZA202408113B (en) Improved process for the manufacture of osimertinib
MX2021013507A (es) Proceso para la preparacion de inhibidores del canal de cloruro ciec-1.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2020006070A (es) Proceso de producción de n-acetil taurinato de magnesio.
MX2023004950A (es) Proceso para purificacion de pleuromutilinas.
MY207512A (en) Process for manufacturing alkanesulfonic acids
HUE067878T2 (hu) Eljárás alkilamidotiazolok gyártásához
IL279168B (en) A process for the preparation of eribulin
MY209549A (en) Process for the preparation of diosmin
CA227224S (en) Inhaler
MY209990A (en) Process for the preparation of dicidal
MX2020013380A (es) Producto refractario, una mezcla para la fabricacion del producto, un procedimiento para la fabricacion del producto asi como un uso del producto.
WO2019094584A3 (en) Method for producing phosphorus chemicals from wet process phosphate
AU2019248350A8 (en) Process for making sarecycline hydrochloride
MX2019002142A (es) Super complemento alimenticio mejorado para perros y su proceso de fabricacion.
CA243085S (en) Tire
MY208976A (en) Process for manufacturing alkanesulfonic acids
MY209585A (en) Process for preparing the dialdehyde of vinylcyclohexene
CA221753S (en) Cup